This group suggested that API treatment (150 mg/kg) significantly suppressed the growth of B16-F10 xenograft tumors and regulated the sensitivity of tumor to immune killing by increased the abundance of CD4+ and CD8+ T cells [31]. The gene discussed is CD8A; the disease is neoplasm.